Omeros Set for Potential Breakout Ahead of FDA Decision
AI Prediction of Omeros Corporation (OMER)
Omeros, with its significant clinical developments and recent financial restructuring, appears poised for potential growth. The expected FDA decisions and advancements in clinical trials for narsoplimab and other pipeline assets could serve as significant catalysts for stock price movement.
OMER Report Information
Prediction Date2025-07-03 01:48:00
Close @ Prediction$3.20
Mkt Cap195m
IPO Date2009-10-08
AI-derived Information
Recent News for OMER
- Aug 15 — Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com)
- Aug 14 — Omeros: Q2 Earnings Snapshot (Associated Press Finance)
- Aug 14 — Omeros Corporation Reports Second Quarter 2025 Financial Results (Business Wire)
- Aug 11 — Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 (Business Wire)
- Jul 25 — Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering (Business Wire)
- Jun 27 — Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA (Business Wire)
- Jun 24 — Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire)
- Jun 3 — Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER) (Zacks)
- May 16 — Q1 2025 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
- May 16 — Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.